Human isoprenylcysteine carboxyl methyltransferase (hIcmt) is a promising anticancer target as it is important for the post-translational modification of oncogenic Ras proteins. We herein report the synthesis and biochemical activity of 41 farnesyl-cysteine based analogs versus hIcmt. We have demonstrated that the amide linkage of a hIcmt substrate can be replaced by a sulfonamide bond to achieve hIcmt inhibition. The most potent sulfonamide-modified farnesyl cysteine analog was 6ag with an IC 50 of 8.8 ± 0.5 lM for hIcmt.
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Proteins that contain a C-terminal CaaX motif (where C-cysteine, aa-any aliphatic amino-acid, X being L, S, M, F or Q) are post-translationally modified by a series of reactions that enable their appropriate cellular targeting, most commonly membrane association (Fig. 1) . K-Ras, one of the >120 proteins having a CaaX box undergoes farnesylation followed by endoproteolyic cleavage of the -aaX residues by Rce-1 and finally methyl esterification of the free carboxylate of the prenylated cysteine by isoprenylcysteine carboxyl methyltransferase (Icmt). Mutant K-Ras, stabilized in the constitutively active GTP-bound conformation, signals continuously resulting in tumorogenesis. Mutant Ras is implicated in 15-20% of all human malignancies and greater than 90% of pancreatic cancers. 1 Inhibition of human Icmt (hIcmt), a 33 kDa integral ER membrane methyltransferase, 2 has been postulated to block the activity of oncogenic Ras. The validity of Icmt as a viable drug target was supported through a knock-out study performed by Bergo et al. 3 and later by Michaelson et al. 4 who showed that ablation of Icmt had a selective effect on Ras signaling. N-Acetyl-S-farnesyl-L-cysteine (AFC) is a substrate for human Icmt (hIcmt) and recent work in our laboratory has shown that amide modified farnesyl cysteine analogs (AMFCs) are low-micromolar inhibitors of hIcmt. 5, 6 Other hIcmt inhibitors have also identified and vary in structure ranging from indoloacetamides, 7 thiosalicylic analogs 8 and prenylated thioacetic acid 9 to halogenated natural products. 10 Due to its membrane localization and its lack of homology with other methyltransferases, there is no structural information on hIcmt. This poses a fundamental challenge to designing Icmt inhibitors. In an effort to understand the requirements for hIcmt inhibition, we hypothesized that isosteric replacements of the amide bond in AMFCs will result in molecules that will retain their interaction with hIcmt and provide more information on inhibition requirements. As a first step to realize this goal, we have focused our attention on evaluating metabolically stable amide bond replacements. Figure 2 shows the structure of the most potent AMFCs synthesized by Donelson et al. 6 Replacement of the amide bond with a metabolically stable and more drug-like isostere is an important goal of our research. Its biological stability and the ease of synthesis led us to explore the sulfonamide bond in AFC based analogs. Herein, we demonstrate that the sulfonamide bond is a viable amide surrogate and that sulfonamide-modified farnesyl cysteine analogs (SMFCs) are lowmicromolar inhibitors of hIcmt.
We synthesized 41 SMFCs through a facile two-step synthetic route from easily available starting materials as depicted in Scheme 1. L-Cysteine was S-farnesylated with farnesyl chloride in 7 N ammonia/methanol. 11 The resulting lipidated amino acid was using aqueous sodium carbonate as the base and dioxane as solvent.
Our preliminary goal in using this SMFC library was to determine the structural requirements for hIcmt inhibition by prenylated cysteine derivatives containing the sulfonamide unit replacement. Chemically diverse sulfonyl chlorides were chosen for the synthesis of the SMFCs. Sulfonyl chlorides with different electronic character, steric bulk and alkyl/aromatic scaffolds were incorporated. All synthesized SMFCs were evaluated as substrates and inhibitors of human Icmt using the vapor diffusion assay (VDA). [12] [13] [14] The structures of the synthesized SMFCs are shown below in Figure 3 . The biochemical evaluation using the VDA revealed that no SMFCs are effective substrates, and are instead moderate inhibitors of hIcmt. The percent inhibition profiles of the SMFCs range from 22% to 60% hIcmt inhibition at 10 lM. Compounds 6a-q inhibited human Icmt poorly, exhibiting less than 45% inhibition at 10 lM.
All other analogs showed greater that 45% inhibition at the test concentration and their percent inhibition values are listed in Figure 3 . Compounds 6r-ab inhibited hIcmt between 45% and 55% at 10 lM and compounds 6ac-ag inhibited hIcmt more than 55% at 10 lM.
IC 50 determinations were carried out for a select group of compounds 6r, 6s, 6ae, 6af and 6ag. Given below in Table 1 are the IC 50 values for the selected compounds.
Our data establish that all SMFCs are relatively poor to moderate inhibitors of hIcmt. Surprisingly, none of the SMFCs are substrates for hIcmt (data not shown). We hypothesize that the presence of the amide bond, or a carbonyl carbon may be necessary for molecules to exhibit substrate activity. All SMFCs inhibit hIcmt, but vary in the strength of inhibition. Highly bulky or rigid analogs (6a, b and h) are poor hIcmt inhibitors, although 6ab and 6y are . Phenoxyphenyl-farnesyl cysteine (POP-FC) and phenoxy-phenyl-3-methylbutenyl-biphenyl farnesyl cysteine (POP-3MB-FC). 6 The metabolically labile amide bond is highlighted.
exceptions. We determined that compounds containing electron withdrawing groups were generally better as hIcmt inhibitors as compared to the ones with electron donating functionalities (6af, ae, ac vs 6c, j, k, l); although there are exceptions (e.g., 6p and 6q). Planar bulk next to the sulfonamide bond also enhances inhibition (6s, w and y).
We next wanted to evaluate the effect of the prenyl group in SMFCs on hIcmt inhibition. To achieve this goal, we synthesized three sulfonamide-modified geranyl cysteine (SMGC) analogs and two analogs where the prenyl chain was replaced by an alkyl chain. These analogs were synthesized in a similar manner to the SMFCs. For the analogs that contain the alkyl chain, the base in the S-alkylation step was changed to 2 M sodium hydroxide in ethanol as described before (see Supplementary data for more detail). 15, 16 Although racemization at the alpha carbon is certainly a possibility, we did not investigate for this possibility. The structures of these analogs are shown in Figure 4 . These analogs were evaluated as inhibitors and substrates of hIcmt using the VDA. The percent inhibition of compounds 7a-c and 8a-b are shown in Table 2 . None of these compounds exhibited substrate activity at 25 lM.
Analogs 7a-c and 8a-b are relatively poor inhibitors of hIcmt as compared to their farnesyl analogs (compounds 6r, 6ae and 6af). These data illustrate that the farnesyl group is highly important for hIcmt inhibition by SMFCs. Increased chain length of the prenyl group appears to be a key factor in hIcmt inhibition. Also, the fact that analog 8a exhibits very similar inhibition to 7b illustrates that the geranyl and the hexyl chains make little difference in the biological activities of these analogs. The fact that compound 8b only showed marginal improvement in inhibition over 8a also strengthens our hypothesis that a longer prenyl chain is a key for hIcmt inhibition. Overall, these data suggest that a determining factor for hIcmt inhibition by SMFCs is the presence of the farnesyl chain, imparting a specific binding interaction rather than simply hydrophobic bulk.
Having determined the role of the farnesyl group in hIcmt inhibition by SMFCs, we next wanted to evaluate the effect of stereochemistry at the alpha carbon of the SMFCs. To achieve this goal, we synthesized the (S) enantiomers of compounds 6ae and 6af. These were synthesized in a manner similar to the one shown in Scheme 1, using D-cysteine in place of L-cysteine. The structures of these analogs are shown in Figure 5 .
Interestingly, analogs 9a-b exhibited identical inhibition profiles at 10 lM as compared to compounds 6ae and 6af. There was little to no difference in the inhibition profiles of the two enantiomers (data not shown). The enantiomers also did not exhibit any substrate activity. The fact that stereochemistry at the alpha carbon did not play a significant role in hIcmt inhibition by SMFCs coupled with the knowledge that the farnesyl group appeared to be a key factor for inhibition leads us to hypothesize that the farnesyl chain in either enantiomer is able to adopt a favorable conformation and enables the SMFC to inhibit hIcmt. Next, we wanted to evaluate the importance of the carboxylate motif of SMFCs for hIcmt inhibition. Toward this aim, we synthesized the methyl ester analog (compound 10) of 6ag (details for synthesis in Supplementary data). Strikingly, this analog exhibited only 10% hIcmt inhibition at 10 lM in the VDA. Although compound 6ag is the most potent SMFC, its ester, compound 10, is a remarkably poor hIcmt inhibitor. This leads us to hypothesize that a deviation from the carboxylate group greatly reduces hIcmt inhibitory activity although more analogs need to be evaluated to corroborate this result.
Finally, we wanted to incorporate the phenoxyphenyl motif ( Fig. 2) that is a part of the most potent AMFCs into the SMFC scaffold. As 2-phenoxy-phenyl sulfonyl chloride is not commercially available, we synthesized it and then coupled it to farnesyl cysteine. Scheme 2 shows the synthesis of POP-SMFC that uses a lithium mediated homolytic C-S bond cleavage in phenoxathin 17 followed by oxidative chlorination 18 to yield the sulfonylchloride (14) is a poorer inhibitor of hIcmt as compared to its amide counterpart. Overall, we have shown that the sulfonamide bond is a viable replacement for the amide bond in AFC derived hIcmt inhibitors. We have also explored the structure-activity relationship of SMFCs as hIcmt inhibitors. The most potent analog, 6ag has an IC 50 of 8.8 ± 0.5 lM. We have demonstrated that the farnesyl group of SMFCs is a necessary structural motif for hIcmt inhibition and that stereochemistry of the alpha carbon does not play a significant role in inhibiting hIcmt. We have also highlighted the importance of the carboxylate motif in SMFCs for hIcmt inhibition, but this result needs further evaluation.
In comparison to the AMFCs, the SMFC library is superior for a number of reasons. Notably, the lead SMFC 6ag exhibits superior ligand efficiency 19 to POP and POP-3-MB. While the AMFC library yielded several substrates for hIcmt, the SMFC library showed no substrate activity. Our lead, 6ag is a step in the right direction because it has a lower molecular weight, a lower C Log P, a higher tPSA and overall a more 'drug-like' character. These encouraging data are fueling our efforts in designing and evaluating novel scaffolds as amide isosteres for achieving potent hIcmt inhibition. 
